Sold as Kybella. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Deoxycholic Acid (sold as Kybella), first approved Apr 29, 2015, with 0 new uses approved and 0 published complete response letters.
| Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With SepsisSepsis · Tanta University | Phase 2 / Phase 3 | Not yet recruiting | Oct 1, 2026 |
| Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | — | Recruiting | Aug 13, 2026 |
| Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic ChildrenThalassemia, Hematopoietic Stem Cell Transplantation · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | — | Recruiting | Jul 24, 2026 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerBladder Urothelial Carcinoma, Bladder Cancer · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Jul 21, 2026 |
| Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal TumorsKidney Cancer · Jinling Hospital, China | Phase 2 | Recruiting | Jun 29, 2026 |
| Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.Chronic Liver Disease · Institute of Liver and Biliary Sciences, India | Not applicable | Not yet recruiting | Jun 23, 2026 |
| Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral HepatitisHepatitis A, Hepatitis E Virus Infection · Combined Military Hospital, Pakistan | Not applicable | Not yet recruiting | Apr 13, 2026 |
| Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic HepatitisImmune-Mediated Cholestasis · University Hospital, Montpellier | Phase 2 | Recruiting | Jan 30, 2026 |
| Apr 29, 2015 | KybellaNDA 206333 · New molecular entity | Abbvie | 6 | Marketed |
| Apr 2, 2021 | Deoxycholic AcidANDA 212296 | Wilshire Pharms Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Abbvie